Price | 1784€+ |
Organism | Human |
Product Type | Tissue derived organoid |
Tissue | Ovary |
Disease | Ovarian Cancer |
Applications
Toxicity
Small molecules
mRNA
Antibody
Cancer vaccine
Immune Cells
Immuno Oncology with TME
Cytotoxic T cell
TIL (Tumor infiltrating lymphocytes)
Regulatory T cell
Macrophage
CAF (Cancer associate fibroblast)
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
Our ovarian cancer organoids exhibit high pathological similarity to patient-derived tumor tissues, expressing key ovarian cancer markers such as CA125, HE4, PAX8 and WT1.
Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with primary tumors, reflecting their differentiation status and histological characteristics.
These pathological marker analyses demonstrate that ovarian cancer organoids faithfully recapitulate the morphological and molecular features of patient tumors, making them a reliable platform for cancer pathology research, drug development, and personalized therapy evaluation.
A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established ovarian cancer (OVC) organoid library.
By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.
Drug sensitivity tests have been conducted using Carboplatin, Cisplatin and Paclitaxel which are widely used in clinical cancer treatment, and drug response data from a subset of OVC organoid models has been collected.
This dataset continues to expand as additional testing is performed.
This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.
Interested in bringing ovarian cancer organoids into your research?
Contact Lambda Biologics to discuss your project with our team.
An ovarian cancer organoid is a three-dimensional (3D) tumor model derived from ovarian cancer patient tissue. These organoids self-organize into structures that preserve key characteristics of the original tumor, including genetic mutations, cellular heterogeneity, and tumor architecture, enabling biologically relevant studies in vitro.
Ovarian cancer organoids retain the genetic mutations, histological features, and intratumoral heterogeneity of the original patient tumor. This enables more clinically relevant evaluation of chemotherapy, targeted therapies, and combination treatments compared with traditional 2D cell models.
Yes. Ovarian cancer organoids are widely used to investigate mechanisms of platinum resistance, a major challenge in ovarian cancer treatment. They allow researchers to evaluate drug sensitivity, test alternative therapies, and explore resistance pathways in a patient-relevant tumor model.
Ovarian cancer organoids support a wide range of applications, including:
Simply contact Lambda Biologics team. Our scientists will review your project needs and provide the right options whether it’s technical guidance, a quote, or custom organoid development.
